Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.
- NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.
- “We are delighted to welcome Hem Pandya as the Executive Chairperson of Intrommune’s Board of Directors and Dr. Jon Rich as a board member,” said Michael Nelson, CEO, Intrommune Therapeutics.
- I look forward to supporting the development of Intrommune’s demonstrated safe and convenient food allergy therapies,” said Hem Pandya.
- Along with serving as Executive Chairman for Intrommune, Mr. Pandya currently serves on the Board of Directors for Exchange Health, LLC, Senores Pharmaceuticals and on the Board of Advisors for Anodyne Nanotech, Inc.